| abstract |
The invention relates to a method for detecting progressive, chronic dementia diseases or a predisposition to such diseases or method for the prognosis of such diseases. For this purpose, the concentration of particular peptides in body fluids or other samples from the patient is measured in a method which can be carried out in a laboratory. The invention further relates to peptides which have been found for determining the presence and/or the grade of the progressive, chronic dementia disease. The invention additionally relates to detection reagents such as antibodies and nucleic acids and the like for detecting said peptides or the corresponding nucleic acids. The invention further relates to pharmaceutical products which comprise the peptides according to the present invention, antibodies directed to said peptides, nucleic acids corresponding to said peptides, peptide antagonists, or peptide agonists for the therapy, diagnosis, prognosis or prophylaxis of neurological diseases, in particular of Alzheimer's disease. The invention further relates to methods for stratifying patients or participants in clinical studies. |